Results 41 to 50 of about 88,666 (249)

Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells

Haematologica, 2008
The α4β1 integrin very late activation antigen-4 (VLA-4) is an α4 (CD49d)/β1 (CD29) heterodimer. It plays a key role in the adhesion of both hematopoietic progenitor cells and leukemic blast cells to bone marrow stromal cells which express the vascular ...
Ulrich Mahlknecht, Christiane Schönbein
doaj   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Haematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani   +9 more
doaj   +1 more source

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia

Haematologica, 2013
Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia.
Alan H. Shih, Stephen S. Chung, Emily K. Dolezal, Su-Jiang Zhang, Omar I. Abdel-Wahab, Christopher Y. Park, Stephen D. Nimer, Ross L. Levine, Virginia M. Klimek   +8 more
doaj   +1 more source

FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia [PDF]

, 2004
Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the ...
Haferlach, Torsten, Hiddemann, Wolfgang, Kern, Wolfgang, Schnittger, Susanne, Schoch, Claudia   +4 more
core   +1 more source

MYC Binding Near Transcriptional End Sites Regulates Basal Gene Expression, Read‐Through Transcription, and Intragenic Contacts

Advanced Science, EarlyView.
MYC is a transcription factor (TF) that binds DNA near transcriptional start sites (TSSs) and within enhancer elements. Here, unappreciated sites of MYC binding in the vicinity of transcriptional end sites (TESs) of many genes in multiple cell types in association with numerous other TFs are described previously.
Huabo Wang, Bingwei Ma, Taylor Stevens, Jessica Knapp, Jie Lu, Edward V. Prochownik   +5 more
wiley   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Advanced Microfluidics for Single Cell‐Based Cancer Research

Advanced Science, EarlyView.
Cutting‐edge microfluidic platforms are transforming single‐cell cancer research. This review highlights advanced technologies, from droplet microfluidics to tumour‐chips, that enable functional and spatial single‐cell analyses. By integrating biosensing, immune components, and patient‐derived materials, these systems offer new insights into tumour ...
Adriana Carneiro, Marta Aranda Palomer, Margarida Esteves, Carolina Rodrigues, José Maria Fernandes, Francisca Oliveira, Alexandra Teixeira, Carlos Honrado, Lorena Dieguez, Sara Abalde‐Cela, Miguel Xavier   +10 more
wiley   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +1 more source

USP8‐Governed MDA5 Homeostasis Promotes Innate Immunity and Autoimmunity

Advanced Science, EarlyView.
This study reveals that USP8 stabilizes MDA5 via AKT‐mediated phosphorylation (Ser718), enhancing their interaction and MDA5 deubiquitination. USP8 inactivation degrades MDA5, suppressing type I IFN and cytokine production. Pharmacological inhibition of USP8/AKT alleviates MDA5‐driven autoimmunity, demonstrating the USP8‐MDA5 axis as a therapeutic ...
Qimin Zhang, Shan Huang, Yan He, Weiwei Wang, Chao Tong, Mengru Ma, Manyu Zhao, Lian Yi, Klaus‐Peter Knobeloch, Peijing Zhang   +9 more
wiley   +1 more source